Three experts in this field discuss in three separate videos: the comorbidity burden in HF patients, the effect of hyperkalemia on use of RAASi and the enabling of RAASi therapy with potassium binders.
Prof. Van der Meer gives an introduction to the symposium about comorbidities in HF with a specific focus on hyperkalemia, that was held during the virtual ESC 2020 congress.
RAAS inhibitors can cause hyperkalemia in HF patients leading to RAASi downtitration or discontinuation. Novel potassium binders may improve management of HF patients by continuation of RAASi.
Prof. Ponikowski discusses the importance of optimization of RAASi treatment through long-term potassium control in HF patients with hyperkalemia.
Prof. Lam discusses important effects of comorbidities in HF patients and how these comorbidities may affect the use of treatments for HF.
Expert discussion on optimizing RAASi treatment through long-term potassium control.